Therefore, for RAS disorder patients with COVID‐19 treatment, administration of ACE2‐Fc in circulation may block SARS‐CoV‐2 infection even in those subjects with induced ACE2 after receipt of ARBs or ACEis treatment. This evidence concerns the gene ACE2 and COVID-19.